Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma

References

• Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466–77
   PubMed Web of Science ®Google Scholar
• Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8:278–92
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203–16
   PubMed Web of Science ®Google Scholar
• Ciccarone V, Spengler BA, Meyers MB, et al. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 1989;49:219–25
   PubMed Web of Science ®Google Scholar
• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106–20
   PubMed Web of Science ®Google Scholar
• Castleberry RP, Pritchard J, Ambros P, et al. The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer 1997;33:2113–16
   PubMed Web of Science ®Google Scholar
• Fukuda M, Miyajima Y, Miyashita Y, Horibe K. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study. J Pediatr Hematol Oncol 2001;23:10–13
   PubMed Web of Science ®Google Scholar
• Hero B, Simon T, Horz S, Berthold F. Metastatic neuroblastoma in infancy: what does the pattern of metastases contribute to prognosis? Med Pediatr Oncol 2000;35:683–7
   PubMedGoogle Scholar
• Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264–79
   PubMed Web of Science ®Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165–73
   PubMed Web of Science ®Google Scholar
• Pinkerton CR, Blanc Vincent MP, Bergeron C, et al. Induction chemotherapy in metastatic neuroblastoma – does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC). Eur J Cancer 2000;36:1808–15
   PubMed Web of Science ®Google Scholar
• Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2000;18:4067–76
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364–76
   PubMed Web of Science ®Google Scholar
• Fiaschi T, Giannoni E, Taddei ML, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013;12:1791–801
   PubMed Web of Science ®Google Scholar
• Jung JH, Im S, Jung ES, Kang CS. Clinicopathological implications of the expression of hypoxia-related proteins in gastric cancer. Int J Med Sci 2013;10:1217–23
   PubMed Web of Science ®Google Scholar
• Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, et al. Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients. J Oral Pathol Med 2012;41:667–74
   PubMed Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 2013;32:5210–19
   PubMed Web of Science ®Google Scholar
• Dungwa JV, Hunt LP, Ramani P. Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas. Hum Pathol 2012;43:1651–60
   PubMed Web of Science ®Google Scholar
• Jogi A, Vallon-Christersson J, Holmquist L, et al. Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. Exp Cell Res 2004;295:469–87
   PubMed Web of Science ®Google Scholar
• Hussein D, Estlin EJ, Dive C, Makin GW. Chronic hypoxia promotes hypoxia-inducible factor-1 alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 2006;5:2241–50
   PubMed Web of Science ®Google Scholar
• Hughes M, Marsden HB, Palmer MK. Histologic patterns of neuroblastoma related to prognosis and clinical staging. Cancer 1974;34:1706–11
   PubMed Web of Science ®Google Scholar
• Lutz W, Stohr M, Schurmann J, et al. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996;13:803–12
   PubMed Web of Science ®Google Scholar
• Lutz W, Fulda S, Jeremias I, et al. MycN and IFN gamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998;17:339–46
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402–8
   PubMed Web of Science ®Google Scholar
• Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005;48:4834–41
   PubMed Web of Science ®Google Scholar
• Jubb AM, Buffa FM, Harris AL. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 2010;14:18–29
   PubMed Web of Science ®Google Scholar
• Kato Y, Yashiro M, Noda S, et al. Expression of a hypoxia-associated protein, carbonic anhydrase-9, correlates with malignant phenotypes of gastric carcinoma. Digestion 2010;82:246–51
   PubMed Web of Science ®Google Scholar
• Luo Y, Cai J, Xue H, et al. Functional SDF1 alpha/CXCR4 signaling in the developing spinal cord. J Neurochem 2005;93:452–62
   PubMed Web of Science ®Google Scholar
• Schweiger T, Kollmann D, Nikolowsky C, et al. Carbonic anhydrase IX is associated with early pulmonary spreading of primary colorectal carcinoma and tobacco smoking. Eur J Cardiothorac Surg 2014;46:92–9
   PubMed Web of Science ®Google Scholar
• Birner P, Jesch B, Friedrich J, et al. Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression. Ann Surg Oncol 2011;18:3330–7
   PubMed Web of Science ®Google Scholar
• Tanaka N, Kato H, Inose T, et al. Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer 2008;99:1468–75
   PubMed Web of Science ®Google Scholar
• Fiaschi T, Giannoni E, Taddei ML, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013;12:1791–801
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364–76
   PubMed Web of Science ®Google Scholar
• Chen J, Rocken C, Hoffmann J, et al. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 2005;54:920–7
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Casini A, Scozzafava A, et al. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:869–73
   PubMed Web of Science ®Google Scholar
• Dubois L, Lieuwes NG, Maresca A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol 2009;92:423–8
   PubMed Web of Science ®Google Scholar
• Dubois L, Peeters S, Lieuwes NG, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 2011;99:424–31
   PubMed Web of Science ®Google Scholar
• Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993;11:738–50
   PubMed Web of Science ®Google Scholar
• Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011;29:121–6
   PubMed Web of Science ®Google Scholar
• van Dijk J, Uemura H, Beniers AJ, et al. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 1994;56:262–8
   PubMed Web of Science ®Google Scholar